Life sciences
Research-administration standards for biotechnology firms
Biotech R&D — across cell + gene therapy, synthetic biology, computational biology, and platform technologies — increasingly relies on academic-industry collaborations, pre-competitive consortia, and data-deposit mandates from journals and funders. CASRAI standards help biotech firms publish responsibly, attribute contributions cleanly, and meet open-data requirements without compromising IP.
~$1.5T global market (2024)
What this sector cares about
Key research-administration concerns
- IP-preserving CRediT statements on academic-industry papers
- Computational-contribution attribution (software, models, pipelines)
- Data + code deposit (NCBI, EMBL-EBI, Zenodo, Software Heritage)
- Synthetic-biology design-file deposit (SBOL, SynBioHub)
- Indigenous data governance (CARE) for biodiversity-based discovery
- Dual-use research of concern (DURC) review
Open lineage nomenclature shows community standards working at biotech speed: viral-genomics teams coordinate naming through public rule sets such as https://pango.network/the-pango-nomenclature-system/statement-of-nomenclature-rules, the same instinct CASRAI applies to contribution and data-deposit standards.
Standards in play
Relevant standards beyond CASRAI
- CRediT
- ORCID
- Software Heritage IDs
- SBOL
- CARE principles
- FAIR4RS (FAIR for research software)
- DURC frameworks
Typical actors
Who's involved
- Founder / CSO
- Computational biologist
- Bench scientist
- Academic collaborator
- IP counsel
- Regulatory affairs
Going deeper
